Figure 3: ABL kinase domain structure bound to imatinib, with locations of 13 resistance mutations indicated. Today, patients with CML are still treated with single-agent BCR-ABL kinase inhibitors ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...